A prospective randomized study of the clinical efficacy and safety of transvenous cardioversion for termination of ventricular tachycardia.
- 1 March 1985
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 71 (3) , 571-578
- https://doi.org/10.1161/01.cir.71.3.571
Abstract
The clinical efficacy and safety of transvenous cardioversion for termination of sustained ventricular tachycardia (VT) were examined by a prospective randomized study design in 22 patients (19 men, three women; mean age 64 +/- 9 years) with organic heart disease and sustained VT. Patients were randomly assigned to undergo an incremental low-energy protocol from 0.03 to 2.2 J (group A, 11 patients) or an incremental high-energy protocol from 0.5 to 10.0 J (group B, 11 patients). Transvenous cardioversion was performed during electrophysiologic studies in the control (drug-free) state and during serial antiarrhythmic drug testing in all patients. Both groups were comparable for demographic, disease and functional status, and electrophysiologic parameters. A total of 77 episodes of VT (group A, 45; group B, 32) were analyzed. The overall efficacy of transvenous cardioversion for termination of VT was 62% (group A 56% vs group B 72%; p less than .01). Antiarrhythmic drug therapy did not significantly enhance efficacy of transvenous cardioversion (control 59% vs drug 65%; p greater than .2). Stepwise discriminant analysis correlated successful transvenous cardioversion with longer VT cycle length (p less than .0005), higher energy (p less than .025), lower energy waveform tilt (p less than .025), shorter time to initial cardioversion attempt (p less than .025), and shorter QRS duration in sinus rhythm (p less than .05). Acceleration of VT was frequent (8% incidence per delivered shock). Thirty-one percent of all incremental shock protocols were terminated because of this complication. After cardioversion, transient arrhythmias were common (bradyarrhythmias 23%, supraventricular tachyarrhythmias 12%). Displacement of electrode catheters after transvenous cardioversion was uncommon (3%).(ABSTRACT TRUNCATED AT 250 WORDS)This publication has 13 references indexed in Scilit:
- Early Experience with an Implantable CardioverterNew England Journal of Medicine, 1984
- Pacing threshold changes after transvenous catheter countershockThe American Journal of Cardiology, 1984
- Role of a catheter lead system for transvenous countershock and pacing during electrophysiologic tests: An assessment of the usefulness of catheter shocks for terminating ventricular tachyarrhythmiasThe American Journal of Cardiology, 1983
- Clinical and electrophysiologic effects of chronic lorcainide therapy in refractory ventricular tachycardiaJournal of the American College of Cardiology, 1983
- Low energy counterchock using an intravascular catheter in an acute cardiac care settingThe American Journal of Cardiology, 1982
- Additional observations on transvenous cardioversion of recurrent ventricular tachycardiaAmerican Heart Journal, 1982
- Clinical transvenous cardioversion of recurrent life-threatening ventricular tachyarrhythmias: Low energy synchronized cardioversion of ventricular tachycardia and termination of ventricular fibrillation in patients using a catheter electrodeAmerican Heart Journal, 1982
- Termination of Malignant Ventricular Arrhythmias with an Implanted Automatic Defibrillator in Human BeingsNew England Journal of Medicine, 1980
- Termination of ventricular tachycardia with bursts of rapid ventricular pacingThe American Journal of Cardiology, 1978
- Relationship between electrode geometry and effectiveness of ventricular defibrillation in the dog with catheter having one electrode in right ventricle and other electrode in superior vena cava, or external jugular vein, or bothCardiovascular Research, 1973